Cathay Fortune International failed to acquire Epigenomics.

Synopsis

Cathay Fortune International, an investment company, failed to acquire Epigenomics, a Germany-based molecular diagnostics company. Financial terms were not disclosed.

Principals

target

Epigenomics

bidder

Cathay Fortune Corporation

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

Market Context

MergerLinks - Cathay Fortune International failed to acquire Epigenomics.